Viridian Therapeutics, Inc.\DE

Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress

- $24.7 million in Lumvoa™ (veligrotug-vvze) net product revenue with more than 100 patients on therapy at the end of Q3 2026 -